Plain-English translation of NCT07303894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a supplement called can help reduce the risk of dangerous blood clots in people with ovarian cancer. People with ovarian cancer who are receiving chemotherapy have a higher risk of developing blood clots, which can be serious. This study will compare the medication to a placebo (a pill with no active ingredient) to see if it can lower markers in the blood that predict clot risk.
Cancer patients, especially those receiving chemotherapy, have a significantly increased risk of life-threatening blood clots. Researchers believe this treatment might help prevent that risk, but they need to test it carefully to see if it works and is safe.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either a placebo or the medication at one of two different daily doses. You will take your assigned pill by mouth while you are receiving your chemotherapy. The study team will monitor you with regular blood tests to measure markers related to blood clot risk and to make sure the treatment is safe. Your participation will continue for the duration of your chemotherapy cycle.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States